Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Clinical Trial to Compare Efficacy, Safety, Tolerability and Immunogenicity of RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration

NCT06470373 is registered in ClinicalTrials.gov with Rophibio, Inc. as lead sponsor.

NCT NCT06470373
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06470373 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Clinical Trial to Compare Efficacy, Safety, Tolerability and Immunogenicity of RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration
Lead sponsor
Rophibio, Inc.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
July 31, 2025
Completion date
September 30, 2026
Enrollment
434 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration (namd)